BBI-940

· Boundless Bio, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BBI-940, covering 2026-04-13 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer [Phase 1]

See pricing